AMRN Bullish. AMRN fell because of SPY drop but recovering wellAMRN is Bullish. AMRN fell because of SPY drop but recovering well. Even on day where the SPY is consolidating. The trend is strong and it is above the Ichimoku Cloud, RSI is bullish
AMRN trade ideas
Amarin Corporation: A Hidden GemGood afternoon.
I would be glad if you subscribe to me in TradingView so you can be the first to read my new ideas. Overly grateful for your likes. In the comments, you can ask questions about the company.
Summary
Technical analysis
On the chart, we can see the imminent completion of corrective wave 2 and the appearance of impulse wave 3.
Several indicators support the uptrend, including the RSI indicator. In addition, this indicator confirms the Elliott Wave labeling.
On the 1D chart, we can see an open gap in the area of $8.4-12.8 per share.
The company's shares are currently in an uptrend. In addition, Amarin shares are just above the EMA 55 and EMA 89, which also confirms the uptrend.
Fundamental Analysis
You can read a complete fundamental analysis of the company in my analytical article in SA.
Conclusion
Considering the above factors, I believe that the growth of Amarin shares will continue.
Disclosure:
This article may not take into account all the risks and catalysts for the stocks described in it. Any part of this analytical article is provided for informational purposes only, does not constitute an individual investment recommendation, investment idea, advice, offer to buy or sold securities, or other financial instruments. The completeness and accuracy of the information in the analytical article are not guaranteed. If any fundamental criteria or events change in the future, I do not assume any obligation to update this article.
AMRN **ON HIGH ALERT** Beat EPS recently. Clearly taking a long recovery from COVID. Amazing positioning if it can hold. Even if it breaks down below I would be setting up 2-3 alerts on this one.
AMARIN - Time to average a bit in short termAmarin has fallen off the cliff recent days based on the court case news. It was on the verge of a breakout before it fell. I think by end of next week, it is still likely to hit 5.3. So maybe still some gain to be done short term or atleast average out longer terms
#AMRN quick 5th wave short today!#AMRN quick 5th wave move short on a 15 min time frame. #BITS indicator confirmed entry with stochastic crossover at the 4th wave point and retest of the 6/4 moving average line. $1.60 move on a $6 stock is a pretty darn good move!
Head and Shoulder Bananza_ContinuedCareful may fail: Support a little below though
Bananza: a situation or event that creates a sudden increase in wealth, good fortune, or profits.
AMRN Rolly Coaster - BTDThis is not a stock I'm familiar with. My dowsing method picked it, so I'm not responsible if it's totally wrong ;) I kid.
I was thrilled to see such awesome options activity, so it has that going for it. Vol isn't crazy high either.
My research is suggesting a pretty swift liquidation in this name. I would not be long, but buy the dip whenever it comes. It may be tomorrow or Friday. At that point it will make a "v bottom" and a new uptrend possibly until the 27th. My initial profit level is $7.70
It also should be noted it has a pretty tight daily squeeze, so there definitely is some energy that could be released. I'm really interested to see how this plays out and it should be noted I'm still learning my dowsing techniques and all that.
Long biased w/ recent settlement with Apotex and tight range.21-May-20 16:10 ET
AMRN
Amarin announces trial to evaluate effects of VASCEPA on patients with COVID-19 (7.28 -0.18)
Amarin today announced support for a clinical trial to investigate the effects of icosapent ethyl (IPE) (VASCEPA) on inflammatory biomarkers and other patient outcomes in individuals with COVID-19. The trial primary endpoint is the effect of VASCEPA versus usual care on high-sensitivity C-reactive protein levels from baseline to 14 days in adults with a COVID-19-positive diagnosis. The clinical study design also includes other endpoints that assess rates and severity of COVID-19 infection in this high-risk group.
The company states, "Based on our current understanding of the biological effects of a COVID-19 infection, including that patients at high risk of cardiovascular disease are at higher risk of mortality and severe effects from a COVID-19 infection, and based on data related to the mechanism of action and effects of VASCEPA in lowering cardiovascular risk in certain high-risk patients, it is believed that VASCEPA could play a beneficial clinical role in helping patients infected by the virus."
14-May-20 14:52 ET
AMRN
Amarin announces VASCEPA data from prespecified and post hoc analyses of REDUCE-IT study (7.64 +0.22)
Amarin today announced that data from the REDUCE-IT study presented at the Society for Cardiovascular Angiography & Interventions 2020 Scientific Sessions,showed that administration of 4 g/day of VASCEPA (icosapent ethyl) resulted in a significant 34% reduction in first coronary revascularizations versus placebo (p<0.0001). Similar reductions of 36% were observed in total, or first and subsequent, revascularizations (p<0.0001).
The analyses from the REDUCE-IT study included several types of coronary revascularization events in statin-treated patients with persistent elevated triglycerides (135-499 mg/dL), who also had either cardiovascular disease or diabetes and additional cardiovascular risk factors.
Prespecified tertiary endpoint analyses showed that times to first revascularization events were significantly reduced by VASCEPA versus placebo across subtypes of intervention, including urgent, emergent, and elective revascularizations, which were reduced by 34% (p<0.0001), 38% (p=0.02), and 32% (p<0.0001), respectively.
In post hoc analyses, VASCEPA significantly reduced percutaneous coronary intervention (PCI) by 32% (p<0.0001) and coronary artery bypass grafting (CABG) by 39% relative to placebo (p=0.0005).
$AMRN - Textbook bull flag$AMRN
Not much to say other then this is a classic bull flag pattern that has appeared over the past few days.
I would look for price to break out of downward movement most likely eyeing $7.15 to set a buy alert.
$5.50 is a hard stop loss for me as that would indicate something is very wrong. However I did see that they just had a lawsuit settlement which is also bullish for them IMO
$AMRN Follow the trend to $8.58
In terms of resistance it is practically non existent until $8.58
News releases is the issue with this stock so be careful and tight stops/
PLEASE DROP A LIKE IF THIS IS HELPFUL, THANKS.
$AMRN $7.75 Fibonacci target
Nice confluence of resistance from horizontal price level,
Fibonacci retrace level.
Channel trend-line
$AMRN upside targets
Waiting for break above Fibonacci resistance
PLEASE GIVE US A LIKE IF YOU APPRECIATE OUR WORK, THANK YOU.
$AMRN upside targets, High risk , high reward
MAy be a case that speculators are in the stock for a quick $$$ after a very erratic selloff.
Jefferies analyst Michael Yee is hosting a conference call with life sciences patent lawyer Jacob Sherkow, who said during the call that he believes Amarin has a 50% chance to win its appeal related to its recent loss in litigation related to generic versions of Vascepa.
Source TheFly.com
$AMRN Jumps on Layer Injunction news
More than 80% chance of Amarin getting injunction, patent lawyer tells Jefferies
Source the fly
